drugset / Trial / NCT00411125

Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women

NCT00411125

Phase 1 Completed 86 enrolled Novartis
RandomizedCrossoverDouble-blindTreatment

Summary

This is a phase I study to analyze bioavailability and pharmacodynamic of two different variants of oral salmon calcitonin (SMC021) in postmenopausal women

Timeline

Start
2006-08
Primary completion
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject salmon calcitonin Unknown 0.8 mg Oral